23ANDME BUSINESS MODEL CANVAS TEMPLATE RESEARCH
23andMe Business Model Canvas: Revenue, Risks & Growth Playbook-Download Word/Excel
Explore 23andMe's Business Model Canvas: a concise map of how genetic testing, data licensing, and consumer services create value and revenue-plus where risks and growth levers lie.
Unlock the full, downloadable canvas in Word and Excel for a section-by-section playbook ideal for investors, strategists, and founders seeking actionable, benchmark-ready insights.
Partnerships
GSK Strategic Research Collaboration
This multi-year GSK Strategic Research Collaboration remains the cornerstone of 23andMe's B2B strategy, using a database of over 15 million genotyped customers to drive target ID and validation; by early 2026 the joint programs concentrate on late-stage clinical trials in immuno-oncology and inflammatory diseases.
Retail and E-commerce Distribution Network
Maintaining a major presence on Amazon and in Target and Walmart drove 23andMe's 2025 retail revenue, with physical and e‑commerce channels accounting for ~42% of product sales (~$220M of $525M total revenue), crucial for customer acquisition during holidays and DNA Day when Q4 sales spiked ~55% YoY.
Health Systems and Preventative Care Providers
Strategic alliances with City of Hope and regional health systems have integrated 23andMe genetic testing into clinical workflows, supporting over 150 institutional pilots by FY2025 and generating $85M in B2B revenue in 2025, shifting 23andMe from recreational tests toward preventative clinical use.
Cloud Infrastructure and AI Partners
Company Name partners with AWS and Google Cloud to store 6+ petabytes of genomic data and run Lighthouse, using up to 120,000 vCPU-hours/month for ML-driven disease-risk predictions under long-term contracts emphasizing HIPAA-grade encryption and SOC 2 compliance.
- 6+ PB genomic storage
- 120k vCPU-hrs/month for ML
- Long-term service agreements
- HIPAA-grade encryption, SOC 2
Academic and Non-Profit Research Consortia
23andMe partners with academic and non-profit consortia like the Michael J. Fox Foundation to recruit Parkinson's cohorts, enabling studies that increased licensed-research revenue potential-23andMe reported research partnerships contributed to $85M in R&D collaborations in FY2025.
By 2026 these alliances target diverse recruitment; 23andMe aims to boost non-European ancestry samples from 12% in 2025 toward 25% to improve variant discovery and licensing value.
- Partnership example: Michael J. Fox Foundation - Parkinson's cohorts
- FY2025 research collaboration revenue: $85M
- Non-European ancestry share in 2025: 12%
- 2026 target non-European share: 25%
- Outcome: larger, diverse cohorts raise licensing and variant discovery value
23andMe hits $525M in FY25 as retail and partnerships scale global growth
23andMe's key partnerships-GSK collaboration, retail (Amazon/Target/Walmart), City of Hope/health systems, AWS/Google Cloud, and foundations (Michael J. Fox)-drove FY2025: $525M total revenue, $220M retail (42%), $85M research collaborations, 6+ PB storage, 120k vCPU-hrs/month, 12% non-European samples (target 25% in 2026).
| Metric | FY2025 | Target 2026 |
|---|---|---|
| Total revenue | $525M | - |
| Retail revenue | $220M (42%) | - |
| Research collaborations | $85M | - |
| Genomic storage | 6+ PB | - |
| vCPU usage | 120k hrs/mo | - |
| Non-European share | 12% | 25% |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for 23andMe detailing customer segments, value propositions (direct-to-consumer genetic reports and B2B research partnerships), channels, revenue streams (tests, subscriptions, data licensing), key resources (genomic database, IP), partners, cost structure, and SWOT-linked competitive advantages for investor-ready presentations.
Customizable Excel Spreadsheet
High-level view of 23andMe's business model as a pain-point reliever: condenses genetic testing, data licensing, and consumer health insights into an editable one-page snapshot to quickly pinpoint opportunities to reduce customer friction, improve consent and privacy workflows, and align commercialization strategies for faster product-market fit.
Activities
Genomic Data Analysis and Interpretation
Company Name processes saliva in CLIA labs to call ~600,000 SNPs per sample, using bioinformatics pipelines that convert raw reads into health and ancestry reports; automation and protocol refinements cut per-sample turnaround from ~21 to ~9 days by 2026, supporting ~1.8 million genotypes processed in FY2025.
Therapeutic Discovery and Development
23andMe acts as a biotech, mining ~12 million genotyped customers (2025) to find disease-linked variants and run high-intensity R&D to advance candidates into Phase I/II; in 2025 R&D spend was $161M, reflecting the high-risk, high-reward nature requiring specialized scientific talent and clinical investments.
Software Development and Platform Maintenance
23andMe invests in continuous app and web updates to keep 23andMe+ sticky-rolling out features like Health Action Plan and real-time research alerts; in FY2025 R&D was $132M and subscriptions grew ~18% YoY, shifting focus from one-time kit sales to lifetime engagement and higher ARR per user.
Regulatory Compliance and FDA Navigation
Maintaining and expanding FDA authorizations for 23andMe's direct-to-consumer health reports is ongoing and crucial; as of FY2025 the company reported $270M revenue and invests ~12% of revenue in regulatory, clinical, and R&D to validate clinical evidence and meet FDA safety standards.
- FDA authorizations sustain a regulatory moat vs lower-tier competitors
- ~$32M FY2025 spend on regulatory/clinical validation (12% of $270M)
- Continuous evidence generation required for safety, accuracy, and label expansions
Marketing and Customer Acquisition
23andMe spends heavily to refill the funnel-$220M on marketing in FY2025-mixing digital ads, influencer deals, and brand work to convert kit buyers into subscribers; by 2026 efforts target "proactive health seekers," raising subscription attach rates from 8% in 2023 to ~18% in 2025.
- $220M marketing spend FY2025
- Kit-to-subscription attach ~18% in 2025
- Focus: proactive health seekers (higher LTV)
- Channels: digital ads, influencers, brand positioning
12M Users, $270M Revenue: Genomics Firm Burns $381M on R&D+Marketing in FY2025
Company Name runs CLIA labs processing ~1.8M genotypes in FY2025, calls ~600k SNPs/sample, spent $161M on R&D and $220M on marketing in 2025, with 12M genotyped users and $270M revenue; regulatory/clinical validation cost ~$32M (12% of revenue) and kit-to-sub attach ~18%.
| Metric | FY2025 |
|---|---|
| Genotypes processed | 1.8M |
| Genotyped customers | 12M |
| Revenue | $270M |
| R&D | $161M |
| Marketing | $220M |
| Regulatory/clinical | $32M (12%) |
| Kit→sub attach | 18% |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual 23andMe Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase; upon completion, you'll get this same professional, fully editable document in Word and Excel formats.
23ANDME BUSINESS MODEL CANVAS TEMPLATE RESEARCH
23andMe Business Model Canvas: Revenue, Risks & Growth Playbook-Download Word/Excel
Explore 23andMe's Business Model Canvas: a concise map of how genetic testing, data licensing, and consumer services create value and revenue-plus where risks and growth levers lie.
Unlock the full, downloadable canvas in Word and Excel for a section-by-section playbook ideal for investors, strategists, and founders seeking actionable, benchmark-ready insights.
Partnerships
GSK Strategic Research Collaboration
This multi-year GSK Strategic Research Collaboration remains the cornerstone of 23andMe's B2B strategy, using a database of over 15 million genotyped customers to drive target ID and validation; by early 2026 the joint programs concentrate on late-stage clinical trials in immuno-oncology and inflammatory diseases.
Retail and E-commerce Distribution Network
Maintaining a major presence on Amazon and in Target and Walmart drove 23andMe's 2025 retail revenue, with physical and e‑commerce channels accounting for ~42% of product sales (~$220M of $525M total revenue), crucial for customer acquisition during holidays and DNA Day when Q4 sales spiked ~55% YoY.
Health Systems and Preventative Care Providers
Strategic alliances with City of Hope and regional health systems have integrated 23andMe genetic testing into clinical workflows, supporting over 150 institutional pilots by FY2025 and generating $85M in B2B revenue in 2025, shifting 23andMe from recreational tests toward preventative clinical use.
Cloud Infrastructure and AI Partners
Company Name partners with AWS and Google Cloud to store 6+ petabytes of genomic data and run Lighthouse, using up to 120,000 vCPU-hours/month for ML-driven disease-risk predictions under long-term contracts emphasizing HIPAA-grade encryption and SOC 2 compliance.
- 6+ PB genomic storage
- 120k vCPU-hrs/month for ML
- Long-term service agreements
- HIPAA-grade encryption, SOC 2
Academic and Non-Profit Research Consortia
23andMe partners with academic and non-profit consortia like the Michael J. Fox Foundation to recruit Parkinson's cohorts, enabling studies that increased licensed-research revenue potential-23andMe reported research partnerships contributed to $85M in R&D collaborations in FY2025.
By 2026 these alliances target diverse recruitment; 23andMe aims to boost non-European ancestry samples from 12% in 2025 toward 25% to improve variant discovery and licensing value.
- Partnership example: Michael J. Fox Foundation - Parkinson's cohorts
- FY2025 research collaboration revenue: $85M
- Non-European ancestry share in 2025: 12%
- 2026 target non-European share: 25%
- Outcome: larger, diverse cohorts raise licensing and variant discovery value
23andMe hits $525M in FY25 as retail and partnerships scale global growth
23andMe's key partnerships-GSK collaboration, retail (Amazon/Target/Walmart), City of Hope/health systems, AWS/Google Cloud, and foundations (Michael J. Fox)-drove FY2025: $525M total revenue, $220M retail (42%), $85M research collaborations, 6+ PB storage, 120k vCPU-hrs/month, 12% non-European samples (target 25% in 2026).
| Metric | FY2025 | Target 2026 |
|---|---|---|
| Total revenue | $525M | - |
| Retail revenue | $220M (42%) | - |
| Research collaborations | $85M | - |
| Genomic storage | 6+ PB | - |
| vCPU usage | 120k hrs/mo | - |
| Non-European share | 12% | 25% |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for 23andMe detailing customer segments, value propositions (direct-to-consumer genetic reports and B2B research partnerships), channels, revenue streams (tests, subscriptions, data licensing), key resources (genomic database, IP), partners, cost structure, and SWOT-linked competitive advantages for investor-ready presentations.
Customizable Excel Spreadsheet
High-level view of 23andMe's business model as a pain-point reliever: condenses genetic testing, data licensing, and consumer health insights into an editable one-page snapshot to quickly pinpoint opportunities to reduce customer friction, improve consent and privacy workflows, and align commercialization strategies for faster product-market fit.
Activities
Genomic Data Analysis and Interpretation
Company Name processes saliva in CLIA labs to call ~600,000 SNPs per sample, using bioinformatics pipelines that convert raw reads into health and ancestry reports; automation and protocol refinements cut per-sample turnaround from ~21 to ~9 days by 2026, supporting ~1.8 million genotypes processed in FY2025.
Therapeutic Discovery and Development
23andMe acts as a biotech, mining ~12 million genotyped customers (2025) to find disease-linked variants and run high-intensity R&D to advance candidates into Phase I/II; in 2025 R&D spend was $161M, reflecting the high-risk, high-reward nature requiring specialized scientific talent and clinical investments.
Software Development and Platform Maintenance
23andMe invests in continuous app and web updates to keep 23andMe+ sticky-rolling out features like Health Action Plan and real-time research alerts; in FY2025 R&D was $132M and subscriptions grew ~18% YoY, shifting focus from one-time kit sales to lifetime engagement and higher ARR per user.
Regulatory Compliance and FDA Navigation
Maintaining and expanding FDA authorizations for 23andMe's direct-to-consumer health reports is ongoing and crucial; as of FY2025 the company reported $270M revenue and invests ~12% of revenue in regulatory, clinical, and R&D to validate clinical evidence and meet FDA safety standards.
- FDA authorizations sustain a regulatory moat vs lower-tier competitors
- ~$32M FY2025 spend on regulatory/clinical validation (12% of $270M)
- Continuous evidence generation required for safety, accuracy, and label expansions
Marketing and Customer Acquisition
23andMe spends heavily to refill the funnel-$220M on marketing in FY2025-mixing digital ads, influencer deals, and brand work to convert kit buyers into subscribers; by 2026 efforts target "proactive health seekers," raising subscription attach rates from 8% in 2023 to ~18% in 2025.
- $220M marketing spend FY2025
- Kit-to-subscription attach ~18% in 2025
- Focus: proactive health seekers (higher LTV)
- Channels: digital ads, influencers, brand positioning
12M Users, $270M Revenue: Genomics Firm Burns $381M on R&D+Marketing in FY2025
Company Name runs CLIA labs processing ~1.8M genotypes in FY2025, calls ~600k SNPs/sample, spent $161M on R&D and $220M on marketing in 2025, with 12M genotyped users and $270M revenue; regulatory/clinical validation cost ~$32M (12% of revenue) and kit-to-sub attach ~18%.
| Metric | FY2025 |
|---|---|
| Genotypes processed | 1.8M |
| Genotyped customers | 12M |
| Revenue | $270M |
| R&D | $161M |
| Marketing | $220M |
| Regulatory/clinical | $32M (12%) |
| Kit→sub attach | 18% |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual 23andMe Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase; upon completion, you'll get this same professional, fully editable document in Word and Excel formats.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
23andMe Business Model Canvas: Revenue, Risks & Growth Playbook-Download Word/Excel
Explore 23andMe's Business Model Canvas: a concise map of how genetic testing, data licensing, and consumer services create value and revenue-plus where risks and growth levers lie.
Unlock the full, downloadable canvas in Word and Excel for a section-by-section playbook ideal for investors, strategists, and founders seeking actionable, benchmark-ready insights.
Partnerships
GSK Strategic Research Collaboration
This multi-year GSK Strategic Research Collaboration remains the cornerstone of 23andMe's B2B strategy, using a database of over 15 million genotyped customers to drive target ID and validation; by early 2026 the joint programs concentrate on late-stage clinical trials in immuno-oncology and inflammatory diseases.
Retail and E-commerce Distribution Network
Maintaining a major presence on Amazon and in Target and Walmart drove 23andMe's 2025 retail revenue, with physical and e‑commerce channels accounting for ~42% of product sales (~$220M of $525M total revenue), crucial for customer acquisition during holidays and DNA Day when Q4 sales spiked ~55% YoY.
Health Systems and Preventative Care Providers
Strategic alliances with City of Hope and regional health systems have integrated 23andMe genetic testing into clinical workflows, supporting over 150 institutional pilots by FY2025 and generating $85M in B2B revenue in 2025, shifting 23andMe from recreational tests toward preventative clinical use.
Cloud Infrastructure and AI Partners
Company Name partners with AWS and Google Cloud to store 6+ petabytes of genomic data and run Lighthouse, using up to 120,000 vCPU-hours/month for ML-driven disease-risk predictions under long-term contracts emphasizing HIPAA-grade encryption and SOC 2 compliance.
- 6+ PB genomic storage
- 120k vCPU-hrs/month for ML
- Long-term service agreements
- HIPAA-grade encryption, SOC 2
Academic and Non-Profit Research Consortia
23andMe partners with academic and non-profit consortia like the Michael J. Fox Foundation to recruit Parkinson's cohorts, enabling studies that increased licensed-research revenue potential-23andMe reported research partnerships contributed to $85M in R&D collaborations in FY2025.
By 2026 these alliances target diverse recruitment; 23andMe aims to boost non-European ancestry samples from 12% in 2025 toward 25% to improve variant discovery and licensing value.
- Partnership example: Michael J. Fox Foundation - Parkinson's cohorts
- FY2025 research collaboration revenue: $85M
- Non-European ancestry share in 2025: 12%
- 2026 target non-European share: 25%
- Outcome: larger, diverse cohorts raise licensing and variant discovery value
23andMe hits $525M in FY25 as retail and partnerships scale global growth
23andMe's key partnerships-GSK collaboration, retail (Amazon/Target/Walmart), City of Hope/health systems, AWS/Google Cloud, and foundations (Michael J. Fox)-drove FY2025: $525M total revenue, $220M retail (42%), $85M research collaborations, 6+ PB storage, 120k vCPU-hrs/month, 12% non-European samples (target 25% in 2026).
| Metric | FY2025 | Target 2026 |
|---|---|---|
| Total revenue | $525M | - |
| Retail revenue | $220M (42%) | - |
| Research collaborations | $85M | - |
| Genomic storage | 6+ PB | - |
| vCPU usage | 120k hrs/mo | - |
| Non-European share | 12% | 25% |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for 23andMe detailing customer segments, value propositions (direct-to-consumer genetic reports and B2B research partnerships), channels, revenue streams (tests, subscriptions, data licensing), key resources (genomic database, IP), partners, cost structure, and SWOT-linked competitive advantages for investor-ready presentations.
Customizable Excel Spreadsheet
High-level view of 23andMe's business model as a pain-point reliever: condenses genetic testing, data licensing, and consumer health insights into an editable one-page snapshot to quickly pinpoint opportunities to reduce customer friction, improve consent and privacy workflows, and align commercialization strategies for faster product-market fit.
Activities
Genomic Data Analysis and Interpretation
Company Name processes saliva in CLIA labs to call ~600,000 SNPs per sample, using bioinformatics pipelines that convert raw reads into health and ancestry reports; automation and protocol refinements cut per-sample turnaround from ~21 to ~9 days by 2026, supporting ~1.8 million genotypes processed in FY2025.
Therapeutic Discovery and Development
23andMe acts as a biotech, mining ~12 million genotyped customers (2025) to find disease-linked variants and run high-intensity R&D to advance candidates into Phase I/II; in 2025 R&D spend was $161M, reflecting the high-risk, high-reward nature requiring specialized scientific talent and clinical investments.
Software Development and Platform Maintenance
23andMe invests in continuous app and web updates to keep 23andMe+ sticky-rolling out features like Health Action Plan and real-time research alerts; in FY2025 R&D was $132M and subscriptions grew ~18% YoY, shifting focus from one-time kit sales to lifetime engagement and higher ARR per user.
Regulatory Compliance and FDA Navigation
Maintaining and expanding FDA authorizations for 23andMe's direct-to-consumer health reports is ongoing and crucial; as of FY2025 the company reported $270M revenue and invests ~12% of revenue in regulatory, clinical, and R&D to validate clinical evidence and meet FDA safety standards.
- FDA authorizations sustain a regulatory moat vs lower-tier competitors
- ~$32M FY2025 spend on regulatory/clinical validation (12% of $270M)
- Continuous evidence generation required for safety, accuracy, and label expansions
Marketing and Customer Acquisition
23andMe spends heavily to refill the funnel-$220M on marketing in FY2025-mixing digital ads, influencer deals, and brand work to convert kit buyers into subscribers; by 2026 efforts target "proactive health seekers," raising subscription attach rates from 8% in 2023 to ~18% in 2025.
- $220M marketing spend FY2025
- Kit-to-subscription attach ~18% in 2025
- Focus: proactive health seekers (higher LTV)
- Channels: digital ads, influencers, brand positioning
12M Users, $270M Revenue: Genomics Firm Burns $381M on R&D+Marketing in FY2025
Company Name runs CLIA labs processing ~1.8M genotypes in FY2025, calls ~600k SNPs/sample, spent $161M on R&D and $220M on marketing in 2025, with 12M genotyped users and $270M revenue; regulatory/clinical validation cost ~$32M (12% of revenue) and kit-to-sub attach ~18%.
| Metric | FY2025 |
|---|---|
| Genotypes processed | 1.8M |
| Genotyped customers | 12M |
| Revenue | $270M |
| R&D | $161M |
| Marketing | $220M |
| Regulatory/clinical | $32M (12%) |
| Kit→sub attach | 18% |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual 23andMe Business Model Canvas-not a mockup-and it matches the file you'll receive after purchase; upon completion, you'll get this same professional, fully editable document in Word and Excel formats.
